A-423,579 je histaminski antagonist koji je razvila kompanija Abot laboratorije. On je selektivan za H3 receptor, i ima stimulantno i anoreksično dejstvo u životinjskim studijama, te je potencijalno koristan tretman za gojaznost. A-423,579 ima poboljšane karakteristike u odnosu na druge ranije razvije lekove ove serije. On ima veću efikasnost i nižu toksičnost u istraživanjima na miševima, i trenutno je u kliničkom razvoju.[3][4]
^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (2004). „In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists”. Basic Clin. Pharmacol. Toxicol. 95 (3): 144—52. PMID15447739. doi:10.1111/j.1742-7843.2004.950307.x.
^Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (2005). „Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy”. Inflamm. Res. 54 Suppl 1: S27—9. PMID15928821. doi:10.1007/s00011-004-0412-z.